Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Mise à jour : Il y a 5 ans
Référence : NCT01492088

Femme et Homme

Extrait

The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.


Critère d'inclusion

  • relapsed or refractory Hodgkin Lymphoma ,Relapsed or Refractory Anaplastic Large-cell Lymphoma


Liens